NGM282 Rapidly Improves NAFLD Activity Score (NAS) and Fibrosis in 12 Weeks in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH): Results of a Phase 2 Multi-Center Dose Finding Study
Publication
, Conference
Harrison, SA; Trotter, JF; Paredes, AH; Guy, CD; Bashir, M; Jaros, MJ; Banerjee, R; Baxter, BA; Ling, L; Rossi, S; Somaratne, RM; DePaoli, A
Published in: HEPATOLOGY
October 1, 2018
Duke Scholars
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
October 1, 2018
Volume
68
Start / End Page
66A / 66A
Location
San Francisco, CA
Publisher
WILEY
Conference Name
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics
Citation
APA
Chicago
ICMJE
MLA
NLM
Harrison, S. A., Trotter, J. F., Paredes, A. H., Guy, C. D., Bashir, M., Jaros, M. J., … DePaoli, A. (2018). NGM282 Rapidly Improves NAFLD Activity Score (NAS) and Fibrosis in 12 Weeks in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH): Results of a Phase 2 Multi-Center Dose Finding Study. In HEPATOLOGY (Vol. 68, pp. 66A-66A). San Francisco, CA: WILEY.
Harrison, Stephen A., James F. Trotter, Angelo H. Paredes, Cynthia D. Guy, Mustafa Bashir, Mark J. Jaros, Rajarshi Banerjee, et al. “NGM282 Rapidly Improves NAFLD Activity Score (NAS) and Fibrosis in 12 Weeks in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH): Results of a Phase 2 Multi-Center Dose Finding Study.” In HEPATOLOGY, 68:66A-66A. WILEY, 2018.
Harrison SA, Trotter JF, Paredes AH, Guy CD, Bashir M, Jaros MJ, et al. NGM282 Rapidly Improves NAFLD Activity Score (NAS) and Fibrosis in 12 Weeks in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH): Results of a Phase 2 Multi-Center Dose Finding Study. In: HEPATOLOGY. WILEY; 2018. p. 66A-66A.
Harrison, Stephen A., et al. “NGM282 Rapidly Improves NAFLD Activity Score (NAS) and Fibrosis in 12 Weeks in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH): Results of a Phase 2 Multi-Center Dose Finding Study.” HEPATOLOGY, vol. 68, WILEY, 2018, pp. 66A-66A.
Harrison SA, Trotter JF, Paredes AH, Guy CD, Bashir M, Jaros MJ, Banerjee R, Baxter BA, Ling L, Rossi S, Somaratne RM, DePaoli A. NGM282 Rapidly Improves NAFLD Activity Score (NAS) and Fibrosis in 12 Weeks in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH): Results of a Phase 2 Multi-Center Dose Finding Study. HEPATOLOGY. WILEY; 2018. p. 66A-66A.
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
October 1, 2018
Volume
68
Start / End Page
66A / 66A
Location
San Francisco, CA
Publisher
WILEY
Conference Name
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics